GDP – Page 23 – Pharma.Tips

Electronic signatures misused during system operation – risk-based ERES remediation

“`html Addressing Misuse of Electronic Signatures in System Operations: A Risk-Based Remediation Playbook The increasing reliance on electronic records and electronic signatures (ERES) in the pharmaceutical industry brings significant regulatory…

Hybrid paper-electronic workflows uncontrolled during system operation – inspection evidence requirements

Managing Uncontrolled Hybrid Paper-Electronic Workflows in Pharmaceutical Operations In today’s pharmaceutical landscape, integrating hybrid paper-electronic workflows has become a necessity. However, uncontrolled workflows during system operation can lead to significant…

Shared user credentials during laboratory walkthrough – 483 risk assessment

Risk Assessment for Shared User Credentials During Laboratory Walkthroughs In the pharmaceutical manufacturing sector, maintaining robust data integrity is critical to compliance with Good Distribution Practices (GDP) and the tenets…

Manual data transcription without verification during FDA inspection – 483 risk assessment

Assessing Risks of Manual Data Transcription Without Verification During FDA Inspections As pharmaceutical manufacturing and quality professionals, encountering challenges surrounding data integrity is not new. One of the significant issues…

Shared user credentials during internal audit – 483 risk assessment

Risk Assessment for Shared User Credentials During Internal Audits In today’s highly regulated pharmaceutical environment, the integrity of data and compliance with Good Manufacturing Practices (GMP) is paramount. The use…

Inadequate DI governance during system validation – CAPA effectiveness checks

Managing Inadequate Data Integrity Governance During System Validation: A Practical Playbook for Pharma Professionals In an era where regulatory scrutiny is intensifying, inadequate data integrity governance during system validation poses…

Repeat data integrity lapses during laboratory walkthrough – remediation roadmap regulators expect

Remediation Roadmap for Recurring Data Integrity Lapses Observed During Laboratory Walkthroughs Data integrity is pivotal in pharmaceutical manufacturing and laboratory settings, especially against the backdrop of increasing regulatory scrutiny. When…

Unsecured raw data storage during FDA inspection – CAPA effectiveness checks

“`html Addressing Unsecured Raw Data Storage During FDA Inspections: A Practical Playbook In the pharmaceutical industry, maintaining compliance with data integrity regulations is crucial, especially during FDA inspections. One of…

Shared user credentials during laboratory walkthrough – remediation roadmap regulators expect

Comprehensive Playbook for Managing Shared User Credentials During Laboratory Walkthroughs In the realm of pharmaceutical manufacturing and quality control, maintaining data integrity is vital for compliance and regulatory assurance. Shared…

Inadequate DI governance during data review – 483 risk assessment

Addressing Inadequate Data Integrity Governance During Data Review In the pharmaceutical landscape, inadequate data integrity (DI) governance during data review can lead to significant regulatory scrutiny, including potential Form 483s…

Shared user credentials during internal audit – remediation roadmap regulators expect

Remediation Roadmap for Shared User Credentials in Internal Audits: A Practical Guide Shared user credentials can pose significant risks to data integrity and compliance within pharmaceutical operations. Controlling access and…

Unsecured raw data storage during system validation – CAPA effectiveness checks

“`html Addressing Unsecured Raw Data Storage in System Validation: A Comprehensive Playbook for Pharma Professionals In today’s regulatory landscape, the integrity of raw data during system validation is paramount. Unsecured…